Aripiprazole
Product Images NDC 50090-4160

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-4160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Aripiprazole Figure 1)

A chart titled 'Effect of Other Drugs on Aripiprazole' illustrating the fold change in aripiprazole exposure (AUC and Cmax) with 90% confidence intervals. It compares the effects of various CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and other drugs on aripiprazole levels, showing changes relative to a reference without interacting drugs.*

FDA Label Image

Figure 2 (Aripiprazole Figure 2)

A chart titled 'Effect of Other Drugs on aripiprazole' showing fold change and 90% confidence intervals for dehydro-aripiprazole, measuring AUC and Cmax relative to a reference without interacting drug. It compares the effect of CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam) on aripiprazole pharmacokinetics.*

FDA Label Image

Figure 3 (Aripiprazole Figure 3)

A scatter plot chart illustrating the effect of aripiprazole on the pharmacokinetics (PK) of various other drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The chart displays fold change and 90% confidence intervals for parameters such as AUC and Cmax, comparing change relative to reference without interacting drug.*

FDA Label Image

Figure 4 (Aripiprazole Figure 4)

A scatter plot showing the fold change and 90% confidence intervals of aripiprazole pharmacokinetic parameters (AUC and Cmax) in special populations compared to reference groups. Variables include CYP2D6 metabolizer status, gender, age groups, hepatic impairment (mild to severe), and severe renal impairment, with change relative to reference on the x-axis.*

FDA Label Image

Figure 5 (Aripiprazole Figure 5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold change in AUC and Cmax relative to reference for various factors: CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment. The plot presents data points with confidence intervals comparing poor vs. extensive metabolizers, female vs. male, age 18-64 vs. >65 years, and different degrees of hepatic and renal impairment.*

FDA Label Image

Figure-6 (Aripiprazole Figure 6)

A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over days from randomization. Two groups are compared: one treated with aripiprazole (blue solid line) and the other with placebo (red dashed line). The x-axis shows days from randomization (0 to 182), and the y-axis shows the proportion with relapse (from 0.0 to 1.0). A table below the x-axis indicates the number of subjects at risk over time for each group.*

FDA Label Image

Figure-7 (Aripiprazole Figure 7)

A line graph comparing the proportion of relapse over time for ARIPIPRAZOLE versus placebo. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. ARIPIPRAZOLE is represented by a solid blue line, placebo by a dashed red line. The graph includes a table of the number of subjects at risk for each group at several time points.*

FDA Label Image

Figure-8 (Aripiprazole Figure 8)

A line graph comparing the proportion of subjects with relapse over 364 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis represents the proportion with relapse. The graph includes a legend distinguishing Aripiprazole (solid blue line) and placebo (dashed red line) with numbers of subjects at risk listed below the x-axis.*

FDA Label Image

Aripiprazole Chemical Structure (Aripiprazole Structure)

Chemical structure of aripiprazole showing its molecular arrangement including dichlorophenyl, piperazine, and quinolinone components. The diagram depicts the bonds and ring systems characteristic of aripiprazole's active ingredient.*

FDA Label Image

Label Image (Lbl500904160)

The packaging label for Aripiprazole 5 mg tablets by A-S Medication Solutions. The label includes the NDC 50090-4160-0, product number 6703-0, and indicates 30 tablets per package. It notes each tablet contains 5 mg of aripiprazole and storage instructions to keep at or below 77 degrees Fahrenheit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.